Publications

Detailed Information

Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract

DC Field Value Language
dc.contributor.authorKim, Sang-Eun-
dc.contributor.authorThuy, Tran Thi Thanh-
dc.contributor.authorLee, Ji-Hyun-
dc.contributor.authorRo, Jai Youl-
dc.contributor.authorKong, Yoon-
dc.contributor.authorLee, Dong-Soon-
dc.contributor.authorLee, Sang-Do-
dc.contributor.authorLee, Yun-Song-
dc.contributor.authorOh, Yeon-Mock-
dc.contributor.authorAhn, Jee-Yin-
dc.contributor.authorBae, Young-An-
dc.date.accessioned2012-05-23T01:13:07Z-
dc.date.available2012-05-23T01:13:07Z-
dc.date.issued2009-04-30-
dc.identifier.citationEXPERIMENTAL AND MOLECULAR MEDICINE; Vol.41 4; 277-287ko_KR
dc.identifier.issn1226-3613-
dc.identifier.urihttps://hdl.handle.net/10371/76290-
dc.description.abstractMatrix metalloproteinase-9 (MMP-9) may play an important role in emphysematous change in chronic obstructive pulmonary disease (COPD), one of the leading causes of mortality and morbidity worldwide. We previously reported that simvastatin, an inhibitor of HMG-CoA reductase, attenuates emphysematous change and MMP-9 induction in the lungs of rats exposed to cigarette smoke. However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Presently, we examined the related signaling for MMP-9 induction and the inhibitory mechanism of simvastatin on MMP-9 induction in AMs exposed to cigarette smoke extract (CSE). In isolated rat AMs, CSE induced MMP-9 expression and phosphorylation of ERK and Akt. A chemical inhibitor of MEK1/2 or PI3K reduced phosphorylation of ERK or Akt, respectively, and also inhibited CSE-mediated MMP-9 induction. Simvastatin reduced CSE-mediated MMP-9 induction, and simvastatin-mediated inhibition was reversed by farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP). Similar to simvastatin, inhibition of FPP transferase or GGPP transferase suppressed CSE-mediated MMP-9 induction. Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, I kappa B, and nuclear AP-1 or NF-kappa B activity. Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and I kappa B-NF-kappa B are involved.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SOC MED BIOCHEMISTRY MOLECULAR BIOLOGYko_KR
dc.subjectmacrophages, alveolarko_KR
dc.subjectmatrix metalloproteinases-9ko_KR
dc.subjectsimvastatinko_KR
dc.subjectpulmonary emphysemako_KR
dc.subjectpulmonary disease, chronic obstructiveko_KR
dc.subjectsmokingko_KR
dc.titleSimvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extractko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김상은-
dc.contributor.AlternativeAuthorThuyTran Thi Thanh-
dc.contributor.AlternativeAuthor이지현-
dc.contributor.AlternativeAuthor노재율-
dc.contributor.AlternativeAuthor배영안-
dc.contributor.AlternativeAuthor공윤-
dc.contributor.AlternativeAuthor안지인-
dc.contributor.AlternativeAuthor이동순-
dc.contributor.AlternativeAuthor오연목-
dc.contributor.AlternativeAuthor이상도-
dc.contributor.AlternativeAuthor이윤송-
dc.identifier.doi10.3858/emm.2009.41.4.031-
dc.citation.journaltitleEXPERIMENTAL AND MOLECULAR MEDICINE-
dc.description.citedreferenceHan SW, 2011, J BIOL CHEM, V286, P25416, DOI [10.1074/jbc.M604013200, 10.1074/jbc.M60413200]-
dc.description.citedreferenceBrass DM, 2008, AM J RESP CELL MOL, V39, P584, DOI 10.1165/rcmb.2007-0448OC-
dc.description.citedreferenceYang SR, 2008, AM J RESP CELL MOL, V38, P689, DOI 10.1165/rcmb.2007-0379OC-
dc.description.citedreferenceForonjy R, 2008, AM J PHYSIOL-LUNG C, V294, pL1149, DOI 10.1152/ajplung.00481.2007-
dc.description.citedreferenceReynolds PR, 2008, AM J PHYSIOL-LUNG C, V294, pL1094, DOI 10.1152/ajplung.00318.2007-
dc.description.citedreferenceTakahashi S, 2008, AM J PHYSIOL-LUNG C, V294, pL882, DOI 10.1152/ajplung.00238.2007-
dc.description.citedreferenceRabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO-
dc.description.citedreferenceKim HS, 2007, EXP MOL MED, V39, P106-
dc.description.citedreferenceKONSTANTINOPOUL.PA, 2007, NAT REV DRUG DISCOV, V6, P541-
dc.description.citedreferenceCheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706-
dc.description.citedreferenceLee KW, 2006, INT J CANCER, V119, P1767, DOI 10.1002/ijc.22056-
dc.description.citedreferenceYang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005-
dc.description.citedreferenceJain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901-
dc.description.citedreferenceLee LH, 2005, AM J RESP CRIT CARE, V172, P987, DOI 10.1164/rccm.200501-041OC-
dc.description.citedreferenceLu YB, 2005, J LEUKOCYTE BIOL, V78, P259, DOI 10.1189/jlb.0904498-
dc.description.citedreferenceTakada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200-
dc.description.citedreferenceTurner NA, 2005, FASEB J, V19, P804, DOI 10.1096/fj.04-2852fje-
dc.description.citedreferenceLiao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748-
dc.description.citedreferenceMoodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje-
dc.description.citedreferenceChung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje-
dc.description.citedreferenceMercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200-
dc.description.citedreferenceMoon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435-
dc.description.citedreferenceBARNES PJ, 2004, J COPD, V1, P59-
dc.description.citedreferenceBarnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703-
dc.description.citedreferenceLai WC, 2003, J IMMUNOL, V170, P6244-
dc.description.citedreferenceChurg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC-
dc.description.citedreferenceAnderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4-
dc.description.citedreferenceCulpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC-
dc.description.citedreferenceEberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me2001-0278-
dc.description.citedreferenceRussell REK, 2002, AM J RESP CELL MOL, V26, P602-
dc.description.citedreferenceMeshi B, 2002, AM J RESP CELL MOL, V26, P52-
dc.description.citedreferenceDenoyelle C, 2001, CARCINOGENESIS, V22, P1139-
dc.description.citedreferenceAikawa M, 2001, CIRCULATION, V103, P276-
dc.description.citedreferenceAOSHIBA K, 2001, AM J PHYSIOL-LUNG C, V281, P1392-
dc.description.citedreferenceEberhardt W, 2000, J IMMUNOL, V165, P5788-
dc.description.citedreferenceVan den Steen PE, 2000, BLOOD, V96, P2673-
dc.description.citedreferenceLim S, 2000, AM J RESP CRIT CARE, V162, P1355-
dc.description.citedreferencePunturieri A, 2000, J EXP MED, V192, P789-
dc.description.citedreferenceLaw BK, 2000, J BIOL CHEM, V275, P10796-
dc.description.citedreferenceWang IK, 2000, ONCOLOGY-BASEL, V59, P245-
dc.description.citedreferenceBetsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985-
dc.description.citedreferenceGIBBS DF, 1999, AM J RESP CELL MOL B-
dc.description.citedreferenceDi Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277-
dc.description.citedreferenceOhnishi K, 1998, LAB INVEST, V78, P1077-
dc.description.citedreferenceGEARING AJ, 1998, NATURE, V370, P555-
dc.description.citedreferenceWhyte DB, 1997, J BIOL CHEM, V272, P14459-
dc.description.citedreferenceGum R, 1997, ONCOGENE, V14, P1481-
dc.description.citedreferenceFINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666-
dc.description.citedreferenceKOHL NE, 1993, SCIENCE, V260, P1934-
dc.description.tc9-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share